---
layout: post
title: "开开实业七连板！医药板块持续火热 四成个股业绩预增翻倍 谁将成预增王"
date: 2022-01-11 18:17:17 +0800
categories: emnews
tags: 东财滚动新闻
---
> 今日(1月11日)，医药板块再度爆发，其中，新冠检测、医药商业、中药为首的概念子板块涨幅居前，个股也再次迎来涨停潮。截至收盘，新冠检测板块，天瑞仪器、安旭生物、亚辉龙、科美诊断、千红制药、九安医疗、科华生物涨停；医药商业板块，柳药股份、开开实业、第一药业涨停；中药板块，吉药控股、华森制药、昆药集团、龙津药业、众生药业、东阿阿胶、大理药业涨停，其中，开开实业已录得七连板。（财联社）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1042" data-code="BK1042|90|1" data-code2="BK1042|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1042&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1042_0" data-code="K BK1042|90|1" data-code2="K BK1042|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/sh600272.html" data-code="600272|1|1" data-code2="600272|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600272&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600272_0" data-code="K 600272|1|1" data-code2="K 600272|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>今日(1月11日)，医药板块再度爆发，其中，新冠检测、<span id="bk_90.BK1042"><a href="http://quote.eastmoney.com/unify/r/90.BK1042" class="keytip" data-code="90,BK1042">医药商业</a></span><span id="bkquote_90.BK1042"></span>、<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>为首的概念子板块涨幅居前，个股也再次迎来涨停潮。截至收盘，新冠检测板块，<span id="stock_0.300165"><a href="http://quote.eastmoney.com/unify/r/0.300165" class="keytip" data-code="0,300165">天瑞仪器</a></span><span id="quote_0.300165"></span>、<span id="stock_1.688075"><a href="http://quote.eastmoney.com/unify/r/1.688075" class="keytip" data-code="1,688075">安旭生物</a></span><span id="quote_1.688075"></span>、<span id="stock_1.688575"><a href="http://quote.eastmoney.com/unify/r/1.688575" class="keytip" data-code="1,688575">亚辉龙</a></span><span id="quote_1.688575"></span>、<span id="stock_1.688468"><a href="http://quote.eastmoney.com/unify/r/1.688468" class="keytip" data-code="1,688468">科美诊断</a></span><span id="quote_1.688468"></span>、<span id="stock_0.002550"><a href="http://quote.eastmoney.com/unify/r/0.002550" class="keytip" data-code="0,002550">千红制药</a></span><span id="quote_0.002550"></span>、<span id="stock_0.002432"><a href="http://quote.eastmoney.com/unify/r/0.002432" class="keytip" data-code="0,002432">九安医疗</a></span><span id="quote_0.002432"></span>、<span id="stock_0.002022"><a href="http://quote.eastmoney.com/unify/r/0.002022" class="keytip" data-code="0,002022">科华生物</a></span><span id="quote_0.002022"></span>涨停；<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1042" class="em_stock_key_common" data-code="90,BK1042">医药商业</span>板块，<span id="stock_1.603368"><a href="http://quote.eastmoney.com/unify/r/1.603368" class="keytip" data-code="1,603368">柳药股份</a></span><span id="quote_1.603368"></span>、<span id="stock_1.600272"><a href="http://quote.eastmoney.com/unify/r/1.600272" class="keytip" data-code="1,600272">开开实业</a></span><span id="quote_1.600272"></span>、第一药业涨停；<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>板块，<span id="stock_0.300108"><a href="http://quote.eastmoney.com/unify/r/0.300108" class="keytip" data-code="0,300108">吉药控股</a></span><span id="quote_0.300108"></span>、<span id="stock_0.002907"><a href="http://quote.eastmoney.com/unify/r/0.002907" class="keytip" data-code="0,002907">华森制药</a></span><span id="quote_0.002907"></span>、<span id="stock_1.600422"><a href="http://quote.eastmoney.com/unify/r/1.600422" class="keytip" data-code="1,600422">昆药集团</a></span><span id="quote_1.600422"></span>、<span id="stock_0.002750"><a href="http://quote.eastmoney.com/unify/r/0.002750" class="keytip" data-code="0,002750">龙津药业</a></span><span id="quote_0.002750"></span>、<span id="stock_0.002317"><a href="http://quote.eastmoney.com/unify/r/0.002317" class="keytip" data-code="0,002317">众生药业</a></span><span id="quote_0.002317"></span>、<span id="stock_0.000423"><a href="http://quote.eastmoney.com/unify/r/0.000423" class="keytip" data-code="0,000423">东阿阿胶</a></span><span id="quote_0.000423"></span>、<span id="stock_1.603963"><a href="http://quote.eastmoney.com/unify/r/1.603963" class="keytip" data-code="1,603963">大理药业</a></span><span id="quote_1.603963"></span>涨停，其中，<span web="1" href="http://quote.eastmoney.com/unify/r/1.600272" class="em_stock_key_common" data-code="1,600272">开开实业</span>已录得七连板。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D24812144930875373066_w541h383.jpg" alt="image" width="541" emheight="383" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>三大因素引燃<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK1040" class="em_stock_key_common" data-code="90,BK1040">中药</span>行情，检测行业则受益旺盛需求</strong></p><p>今日(1月11日)，中药、新冠检测板块再度爆发，个股掀起涨停潮。中药板块自去年年末起持续活跃，截止今日收盘，以近20日涨跌幅来统计，<span web="1" href="http://quote.eastmoney.com/unify/r/0.002750" class="em_stock_key_common" data-code="0,002750">龙津药业</span>、<span id="stock_0.300534"><a href="http://quote.eastmoney.com/unify/r/0.300534" class="keytip" data-code="0,300534">陇神戎发</a></span><span id="quote_0.300534"></span>、<span id="stock_0.002349"><a href="http://quote.eastmoney.com/unify/r/0.002349" class="keytip" data-code="0,002349">精华制药</a></span><span id="quote_0.002349"></span>涨幅均翻倍，<span id="stock_0.300026"><a href="http://quote.eastmoney.com/unify/r/0.300026" class="keytip" data-code="0,300026">红日药业</a></span><span id="quote_0.300026"></span>涨近94%，<span id="stock_0.002873"><a href="http://quote.eastmoney.com/unify/r/0.002873" class="keytip" data-code="0,002873">新天药业</a></span><span id="quote_0.002873"></span>涨近87%，<span id="stock_0.000999"><a href="http://quote.eastmoney.com/unify/r/0.000999" class="keytip" data-code="0,000999">华润三九</a></span><span id="quote_0.000999"></span>涨近53%，<span id="stock_1.600129"><a href="http://quote.eastmoney.com/unify/r/1.600129" class="keytip" data-code="1,600129">太极集团</a></span><span id="quote_1.600129"></span>、<span id="stock_0.002603"><a href="http://quote.eastmoney.com/unify/r/0.002603" class="keytip" data-code="0,002603">以岭药业</a></span><span id="quote_0.002603"></span>等9股涨幅逾40%，板块内涨幅逾10%的个股占比达85%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25534333288798026226_w692h347.jpg" alt="image" width="580" emheight="291" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p>中药板块主要受益于政策面利好、需求端旺盛与较高估值性价比。对于后市，<span id="stock_0.000686"><a href="http://quote.eastmoney.com/unify/r/0.000686" class="keytip" data-code="0,000686">东北证券</a></span><span id="quote_0.000686"></span>认为当前需求端、政策端以及估值端共同作用的背景下，后续三个方向有望存在投资机会：受益于消费升级，进行“大健康”领域布局的中药企业、有望受益于改革以及政策福利的中药企业、当前部分估值性价比较高的中药企业。不过也有机构指出，目前中药估值修复后期将迎来<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>验证阶段。</p><p><span id="stock_1.601211"><a href="http://quote.eastmoney.com/unify/r/1.601211" class="keytip" data-code="1,601211">国泰君安</a></span><span id="quote_1.601211"></span><span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>认为，中药板块相对医药整体的极值折价已显著收敛，<strong>虽有少量个股估值仍低于板块均值，但其整体估值性价比正在逐步消失</strong>。尽管不排除市场惯性将在短期进一步推升板块出现更高的市场溢价，但估值体系倘若要被系统性地修正甚至锚定，行业底层逻辑的变化仍需得到业绩的验证，<strong>尤其短期少数公司提价逻辑也随着财报季渐行渐近即将接受验证，这或将推动个股分化。</strong>另一方面，随着其他业绩高景气赛道微观结构恶化的改善、并正形成估值与景气度的新平衡，也将对中药板块的估值与增长的匹配度形成约束。</p><p>新冠检测板块近期的景气度则来自于检测产品的旺盛需求，目前，海外疫情仍陷焦灼状态，对于新冠检测产品需求剧增，多家上市公司旗下检测产品获得欧美等国认证，外贸订单快速增长有望刺激业绩大幅增厚，由此带动板块个股迎来爆发。截止今日(1月11日)，以近20日涨跌幅来统计(除今年上市与ST股外)，<span web="1" href="http://quote.eastmoney.com/unify/r/0.002432" class="em_stock_key_common" data-code="0,002432">九安医疗</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688075" class="em_stock_key_common" data-code="1,688075">安旭生物</span>涨幅翻番，<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>、<span id="stock_1.688606"><a href="http://quote.eastmoney.com/unify/r/1.688606" class="keytip" data-code="1,688606">奥泰生物</a></span><span id="quote_1.688606"></span>、<span id="stock_1.688068"><a href="http://quote.eastmoney.com/unify/r/1.688068" class="keytip" data-code="1,688068">热景生物</a></span><span id="quote_1.688068"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300165" class="em_stock_key_common" data-code="0,300165">天瑞仪器</span>、<span id="stock_0.002584"><a href="http://quote.eastmoney.com/unify/r/0.002584" class="keytip" data-code="0,002584">西陇科学</a></span><span id="quote_0.002584"></span>涨幅逾50%。</p><center><img src="https://dfscdn.dfcfw.com/download/D25740272580126336237_w692h315.jpg" alt="image" width="580" emheight="264" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>四成个股业绩同比翻番，<span web="1" href="http://quote.eastmoney.com/unify/r/1.688068" class="em_stock_key_common" data-code="1,688068">热景生物</span>暂列医药预增王</strong></p><p>医药板块持续活跃，一方面受益于行业整体的高景气度，另一方面，近期陆续公布的业绩预告也为火热行情添砖加瓦。截止1月11日，已有16只医药股(除ST股外)披露2021年年度业绩预告，整体来看表现尚可，仅1股归母<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>为负，显示亏损，归母净利润增速方面也普遍显示正增长。年度预告业绩增速翻倍(预告归母净利润增长下限大于100%)的个股共有6只，占比达37.5%。</p><center><img src="https://dfscdn.dfcfw.com/download/D24902693617017626941_w1176h703.jpg" alt="image" width="580" emheight="347" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><span web="1" href="http://quote.eastmoney.com/unify/r/1.688068" class="em_stock_key_common" data-code="1,688068">热景生物</span>以16.8倍至19.97倍的业绩增速暂列医药板块预增王，<span id="stock_0.002411"><a href="http://quote.eastmoney.com/unify/r/0.002411" class="keytip" data-code="0,002411">延安必康</a></span><span id="quote_0.002411"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002317" class="em_stock_key_common" data-code="0,002317">众生药业</span>、<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>、<span id="stock_1.688690"><a href="http://quote.eastmoney.com/unify/r/1.688690" class="keytip" data-code="1,688690">纳微科技</a></span><span id="quote_1.688690"></span>、<span id="stock_0.300639"><a href="http://quote.eastmoney.com/unify/r/0.300639" class="keytip" data-code="0,300639">凯普生物</a></span><span id="quote_0.300639"></span>紧随其后，其中，热景生物、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002932" class="em_stock_key_common" data-code="0,002932">明德生物</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300639" class="em_stock_key_common" data-code="0,300639">凯普生物</span>均受益于海外新冠检测试剂收入增长，<span web="1" href="http://quote.eastmoney.com/unify/r/1.688690" class="em_stock_key_common" data-code="1,688690">纳微科技</span>受益于公司产品的销售额较上年有较大幅度增长；<span web="1" href="http://quote.eastmoney.com/unify/r/0.002411" class="em_stock_key_common" data-code="0,002411">延安必康</span>则受益于子公司生产的新能源产品与资金补贴；<span web="1" href="http://quote.eastmoney.com/unify/r/0.002317" class="em_stock_key_common" data-code="0,002317">众生药业</span>2021年扭亏为盈，主要原因是上年业绩受商誉减值计提影响导致亏损。</p><p>目前，整个医药板块呈现分化走势，中药、新冠检测概念持续走强，去年的明星赛道例如CRO等则开年遇冷。<span id="stock_1.601878"><a href="http://quote.eastmoney.com/unify/r/1.601878" class="keytip" data-code="1,601878">浙商证券</a></span><span id="quote_1.601878"></span>认为，自2022年开年以来，CXO标的持续调整，市场的主要担忧集中于：市场担忧新冠订单后，行业2023年后业绩的持续性；通过产能周期分析，认为2023年后增长可能降速。不过，<span web="1" href="http://quote.eastmoney.com/unify/r/1.601878" class="em_stock_key_common" data-code="1,601878">浙商证券</span>指出，相比于市场更看好业绩增长的超预期及持续性，建议淡化新冠的事件性影响，更关注产业链地位的提升及供给能力的加速提升。</p><p>随着上市公司陆续披露其2021年报预告，一些业绩超出市场预期的个股也有望迎来爆发式上涨，而全年业绩往往也可以从此前三季度的业绩表现进行预测。从2021年前三季度归母净利润同比增速来看，热景生物、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002411" class="em_stock_key_common" data-code="0,002411">延安必康</span>、<span id="stock_0.000597"><a href="http://quote.eastmoney.com/unify/r/0.000597" class="keytip" data-code="0,000597">东北制药</a></span><span id="quote_0.000597"></span>、<span id="stock_0.002900"><a href="http://quote.eastmoney.com/unify/r/0.002900" class="keytip" data-code="0,002900">哈三联</a></span><span id="quote_0.002900"></span>、<span id="stock_0.002758"><a href="http://quote.eastmoney.com/unify/r/0.002758" class="keytip" data-code="0,002758">浙农股份</a></span><span id="quote_0.002758"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600129" class="em_stock_key_common" data-code="1,600129">太极集团</span>、<span id="stock_0.002433"><a href="http://quote.eastmoney.com/unify/r/0.002433" class="keytip" data-code="0,002433">太安堂</a></span><span id="quote_0.002433"></span>、<span id="stock_0.300358"><a href="http://quote.eastmoney.com/unify/r/0.300358" class="keytip" data-code="0,300358">楚天科技</a></span><span id="quote_0.300358"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688298" class="em_stock_key_common" data-code="1,688298">东方生物</span>位居增速前十。</p><p>2021年前三季度归母净利润同比增速前20的医药公司：</p><center><img src="https://dfscdn.dfcfw.com/download/D25282655621119554672_w1493h772.jpg" alt="image" width="580" emheight="300" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：财联社）</p>

<http://finance.eastmoney.com/news/1345,202201112243907919.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)